Abstract
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal lurtotecan, OSI-211 (formerly known as NX211), given as a short intravenous infusion on days 1, 2, and 3 every three weeks. Experimental design: Thirty-seven patients were enrolled and treated in a dose escalation study from a starting dose of 0.15 mg/m2 daily × 3 to 2.1 mg/m2 daily × 3. Detailed pharmacokinetic analyses of blood were done on both days 1 and 3 of the first cycle and toxicity was monitored. Results: Two MTDs were defined; one for patients defined as minimally pretreated and one for those heavily pretreated. Dose limiting toxicity was myelosuppression: primarily thrombocytopenia although neutropenia was also noted. The MTD was 2.1 mg/m2/d (total dose of 6.3 mg/m2) in minimally pretreated patients and 1.8 mg/m2/d (5.4 mg/m2 total dose) in heavily pretreated patients. Pharmacokinetics revealed that AUC and C max increased with dose and were significantly higher than that of free lurtotecan (AUC approx. 100 fold higher). The half life and duration of the active lactone form were also significantly longer than historical data on free drug. Two partial responses were seen, one each in a patient with breast and ovarian cancer. Conclusions: Two Phase II recommended doses were established for OSI-211 given as a daily × 3 schedule every three weeks. The recommended phase II dose is 1.8 mg/m2 daily × 3 for minimally pretreated patients and 1.5 mg/m2 for those heavily pretreated. Phase II studies should be initiated in sensitive tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Emerson DL, Besterman JM, Brown HR et al.: In vivo antitumour activity of two new seven substituted water-soluble camptothecin analogues. Cancer Res 55: 603–609, 1995
Gerrits CJ, Creemers GJ, Schellens JH et al.: Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily × 5 intravenous administration. Br J Cancer 73(6): 744–750, 1996
O’Dwyer P, Pas Arez L et al.: Phase I trial of the topoisomerase I inhibitor GG211 as a 72 hour infusion. Eur J Cancer 31(Suppl 5): S193, 1995
Khater C, Twelves C et al.: Phase I trial f the topoisomerase inhibitor GG211 as a 21 day continuous infusion. Proc Am Soc Clin Oncol 15: 483a, 1996
Sessa C, Wanders J, Roelvink M et al.: Second line treatment of small cell lung cancer with the camptothecin derivative FGI147211: A study of the EORTC Early Clinical Studies Group (ECSG). Ann of Oncol 11: 207–210, 2000
Wanders J, Oosterom Van AT et al.: A phase II study with GI147211 in ovarian cancer. Eu J Cancer 33(Suppl 8): S118, 1997
Wanders J, ten Bokkel Huinink WW et al.: Phase II studies with GI147211 (GI) in breast, colorectal, and nonsmall cell lung cancer. Eur J Cancer 33(Suppl 8): S705, 1997
Heinrich B, Lehnert M et al.: Phase II trial of GI 147211 in locally advanced or metastatic non small cell lung cancer. Proc Am Soc Clin Oncol 16: 470a, 1997
Emerson DL, Bendele R, Brown E et al.: Antitumor efficacy, pharmacokinetics and biodistribution of NX211: A low clearance liposomal formulation of lurtotecan. Clin Cancer Res 6: 2903–2912, 2000
Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, LeRay JD, Brown EN, Hamilton M, Dihel L, Ptaszynski M, Bendele RA, Richardson FC: Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-Cancer Drugs 13(3): 235–245, 2001
Eisenhauer E, Verweij J, Rothenberg MI et al.: Phase I Evaluation of Liposomal topoisomerase I inhibitor, NX211, administered by three schedules to patients with advanced solid tumours. Proc Am Soc Clin Oncol 20: 409a, 2001
Felton SA, Hammond LA, Hao D et al.: A Phase I study of NX211, Liposomal Lurtotecan, given as an intravenous infusion on days 1, 8, 15, and 22 every six weeks in patients with advanced solid tumours. Proc Am Soc Clin Oncol 20: 413a, 2001
Kehrer DFS, Bos AM, Verweij J et al.: Phase I and pharmacologic study of liposomal lurtotecan (NX 211): Urinary excretion predicts hematologic toxicity. J Clin Oncol 20: 1222–1231, 2002
Rowinsky E, Johnson TR, Geyer CE et al.: DX-8951f, a hexacyclic campthothecin nalog, on a daily-times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 18: 3151–3163, 2000
Rothenberg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 8: 837–855, 1997
Slichenmyer WJ, Rowinsky EK, Donehower RC et al.: The current status of camptothecin analogues as antitumour agents. J Natl Cancer Inst 85: 271–291, 1993
Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden T: Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60: 3389–3393, 2000
Bos AME, Kehrer D, Sparreboom A et al.: A Phase I study of NX211 (liposomal lurtotecan) given as an IV infusion on day 1 every 3 weeks in patients with solid tumours. Pro Am Soc Clin Oncol 19: 197a, 2000
Eisenhauer E, Gelmon K, Hirte, H, Fisher B, Walsh W, Ptaszynski M, Onetto N, Zee B: Predictors of inter-patient (pt) toxicity in a phase I trial of NX211 given in a daily × 3 intravenous infusion schedule every 3 weeks. (Poster, Abstract 240) Presented at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, November 7–10, 2000, Amsterdam
Eisenhauer E, Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Onetto N, Zee B: Predictors of inter-patient toxicity in a phase I trial of NX211 given in a daily × 3 intravenous infusion schedule ever three weeks. Clin Cancer Research 6(Supp): 240a, 2000
Mayer LD, Cullus PR, Bally MB: Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes. In Lassic D, Papahadjopoulos D (eds) Medical Applications of Liposomes. Amsterdam, Elsevier Press, 1998, 231–256
Rahman A, Treat J, Roh JK et al.: A phase I clinical trial and pharmacokinetic evaluation of liposome encapsulated doxorubicin. J Clin Oncol 8: 1093–1100, 1990
Gelmon KA, Tolcher A, Diab AR et al.: Phase I study of liposomal vincristine. J Clin Oncol 17: 697–705, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gelmon, K., Hirte, H., Fisher, B. et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs 22, 263–275 (2004). https://doi.org/10.1023/B:DRUG.0000026252.86842.e2
Issue Date:
DOI: https://doi.org/10.1023/B:DRUG.0000026252.86842.e2